Five research projects with commercial potential receive sustaining funding through Harvard’s Physical Sciences & Engineering Accelerator.

Twelve advanced research projects aimed at developing new therapies and diagnostics receive support in 2015-16 from Harvard’s Blavatnik Biomedical Accelerator.

NEWTON, Mass.--(BUSINESS WIRE)--Macrolide Pharmaceuticals, a new company with groundbreaking technology to develop novel antibiotics, completed a Series A financing of $22 million led by Novartis Venture Fund, Gurnet Point Capital, Roche Ventures, and SROne. The financing follows a worldwide license agreement between Harvard's Office of Technology Development and the company, providing exclusive rights to the technology.

The Blavatnik Fellowship in Life Science Entrepreneurship kicked-off a second exciting year with reception to welcome the new fellows.